BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Novatrials opens advanced Phase 1 clinical trials facility in Australia to meet global demand

June 16, 2025 | News | By Ankit Kankar | ankit.kankar@mmactiv.com

State-of-the-art 2,000 sqm Newcastle site now accepting proposals, offering global sponsors full-spectrum trial capabilities with unmatched efficiency and value



Novatrials, Australia's largest independently owned clinical trials site, is excited to announce its newly constructed Phase 1 facility, is now accepting study proposals. Renowned for delivering exceptional Phase 1, 2 and 3 services to leading global pharmaceutical and biotech companies for over a decade, Novatrials has expanded to meet rising demand with this state-of-the-art facility.

Spanning over 2,000 square meters, this brand-new, purpose-built site is fully equipped with cutting-edge technology. Once fully operational, it will feature a 31-bed inpatient unit, dedicated outpatient consultation rooms, a full suite of business offices, a comprehensive clinical laboratory, an on-site compounding pharmacy, and other specialized services.

Situated in Newcastle, New South Wales, the site integrates cutting-edge infrastructure, expert clinical staff, and a diverse participant base. It provides comprehensive trial services, from first-in-human to late-phase studies, with expertise in obesity, dermatology, endocrinology, cardiology, neurology, pain, osteoarthritis, vaccines and women's health.

"With the launch of this facility, Novatrials has uniquely positioned itself to offer global sponsors the highest quality research in a region that affords unparalleled speed and value." said Prof. Jennifer Martin, Medical Director. "This site has been built from the ground up to offer biotech and pharmaceutical companies exceptional results at an unmatched value."

Australia has quickly become a premier destination for clinical trials due to its streamlined ethics and regulatory processes, extensive patient recruitment pool, competitive exchange rates, and attractive tax incentives. With this new facility, Novatrials has uniquely positioned itself to allow clients to leverage these advantages.